| This study (n=338) |
AMD |
Singapore |
0.89 |
Mean BEVA: 0.20
Mean WEVA: 0.65
Mean Weighted VA: 0.31 |
BEVA: −0.291
WEVA: −0.247
Weighted VA: −0.305 |
| Soubrane et al6 (n=401) |
AMD |
France, Germany, Spain, UK, Canada |
0.65 |
Mean BEVA: 0.6 |
Not assessed, but no association found with BEVA |
| Cruess et al33 (n=67) |
AMD |
Canada |
0.64 |
BEVA
>20/40: 14.9%
>20/80–20/40: 10.4%
>20/200–20/80: 31.3%
>20/400–20/200: 25.4%
20/400 or worse: 13.4% |
Not assessed, but no association found with BEVA |
| Lotery et al34 (n=75) |
Neovascular AMD |
UK |
0.67 |
Better than 20/40 to worse than 20/400; no percentages given |
Not assessed, but no association found with BEVA |
| Espallargues et al5 (n=209) |
AMD |
UK |
0.72 |
Mean BEVA: 1.01
Mean WEVA: 1.68 |
BEVA: −0.09 |
| Clark et al35 (n=19) |
Post-operative endophthalmitis |
Australia |
0.66 |
No visual impairment (VI): 47%
Unilateral VI: 47%
Bilateral VI: 6% |
Not assessed |
| Aspinall et al36 (n=72) |
Glaucoma |
UK |
0.76 |
78% with VA better than 6/12 in both eyes |
Not assessed, but significant association found with VA (P<0.01) |
| Kobelt et al37 (n=199) |
Glaucoma |
Sweden |
0.80 |
Mean BEVA: 0.63
Mean WEVA: 0.87
Weighted VA: 0.80 |
Not assessed, but no association found |
| Lloyd et al38 (n=101) |
Diabetic retinopathy |
UK |
Not assessed |
6/6–6/9: 67%
6/12–6/18: 13%
6/24–6/36: 10%
6/60–6/120: 7%
CF–HM: 3% |
Not assessed; R2=0.123 |
| Polack et al39 (n=217) |
Cataract |
Bangladesh |
Not assessed |
BEVA
<6/24–6/60: 26%
<6/60–3/60: 19%
<3/60–>PL: 14%
PL: 41% |
Not assessed |
| Polack et al40 (n=196) |
Cataract |
Kenya |
Not assessed |
BEVA
<6/24–6/60: 39.8%
<6/60–3/60: 20.9%
<3/60–>PL: 18.4%
PL: 20.9% |
Not assessed |
| Datta et al41 (n=306) |
Cataract |
UK |
0.73 |
Mean BEVA: 0.28 |
Standardised β: 0.01 |
| Lengalaan et al42 (n=128) |
Visually impaired |
Netherlands |
0.73 |
Not reported |
Not assessed |
| Rajagopalan et al43 (n=32) |
Sjögren's syndrome keratoconjunctivitis sicca |
USA, Canada |
0.74 |
Not reported |
Not assessed |
